Skip to main content
. 2016 Sep 12;28(3):823–836. doi: 10.1681/ASN.2015080898

Figure 2.

Figure 2.

Increased kidney RelB and NFκB2 expression and evidence for noncanonical NFκB activation in acute folate nephropathy. Kidney mRNA levels (A and C) were assessed by quantitative RT-PCR and protein levels by Western blot (B and D). (A) RelB mRNA, *p<0.01 versus vehicle. (B) RelB protein, *p<0.03 versus vehicle. (C) NFκB2 mRNA, *p<0.01 versus vehicle. (D) NFκB2 p100 and p52 proteins, representative Western blot. (E) NFκB2 p100 and p52 protein quantification, *p<0.03 and **p<0.05 versus vehicle. NFκB2 p100 is processed to NFκB p52 by the proteasome. (F) Increased nuclear DNA-binding activity of NFκB2 p52 and RelB in folate nephropathy. A DNA-binding ELISA was used to quantify DNA-binding activity of NFκB2 p52 and RelB in nuclei obtained from kidneys 24 hours after induction of folate nephropathy or vehicle administration. *p<0.01 versus vehicle; n=6 animals per group.